Loading
A phase 3 trial testing SGM-101 in colorectal cancer, now recruiting.
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer is a phase 3 interventional study registered as NCT03659448, led by Surgimab, and recruiting on the registry. Official title: Multicenter, Open-label, Randomised, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumour and Metastases in Patients Undergoing Surgery for Colorectal Cancer. Planned enrolment is 300 participants (estimated). The study started in 2019-06-17 and primary completion is expected in 2024-11. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SGM-101, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/